Oral iron supplementation after blood donation: a randomized clinical trial
- PMID: 25668261
- PMCID: PMC5094173
- DOI: 10.1001/jama.2015.119
Oral iron supplementation after blood donation: a randomized clinical trial
Abstract
Importance: Although blood donation is allowed every 8 weeks in the United States, recovery of hemoglobin to the currently accepted standard (12.5 g/dL) is frequently delayed, and some donors become anemic.
Objective: To determine the effect of oral iron supplementation on hemoglobin recovery time (days to recovery of 80% of hemoglobin removed) and recovery of iron stores in iron-depleted ("low ferritin," ≤26 ng/mL) and iron-replete ("higher ferritin," >26 ng/mL) blood donors.
Design, setting, and participants: Randomized, nonblinded clinical trial of blood donors stratified by ferritin level, sex, and age conducted in 4 regional blood centers in the United States in 2012. Included were 215 eligible participants aged 18 to 79 years who had not donated whole blood or red blood cells within 4 months.
Interventions: One tablet of ferrous gluconate (37.5 mg of elemental iron) daily or no iron for 24 weeks (168 days) after donating a unit of whole blood (500 mL).
Main outcomes and measures: Time to recovery of 80% of the postdonation decrease in hemoglobin and recovery of ferritin level to baseline as a measure of iron stores.
Results: The mean baseline hemoglobin levels were comparable in the iron and no-iron groups and declined from a mean (SD) of 13.4 (1.1) g/dL to 12.0 (1.2) g/dL after donation in the low-ferritin group and from 14.2 (1.1) g/dL to 12.9 (1.2) g/dL in the higher-ferritin group. Compared with participants who did not receive iron supplementation, those who received iron supplementation had shortened time to 80% hemoglobin recovery in both the low-ferritin (mean, 32 days, interquartile range [IQR], 30-34, vs 158 days, IQR, 126->168) and higher-ferritin groups (31 days, IQR, 29-33, vs 78 days, IQR, 66-95). Median time to recovery to baseline ferritin levels in the low-ferritin group taking iron was 21 days (IQR, 12-84). For participants not taking iron, recovery to baseline was longer than 168 days (IQR, 128->168). Median time to recovery to baseline in the higher-ferritin group taking iron was 107 days (IQR, 75-141), and for participants not taking iron, recovery to baseline was longer than 168 days (IQR, >168->168). Recovery of iron stores in all participants who received supplements took a median of 76 days (IQR, 20-126); for participants not taking iron, median recovery time was longer than 168 days (IQR, 147->168 days; P < .001). Without iron supplements, 67% of participants did not recover iron stores by 168 days.
Conclusions and relevance: Among blood donors with normal hemoglobin levels, low-dose iron supplementation, compared with no supplementation, reduced time to 80% recovery of the postdonation decrease in hemoglobin concentration in donors with low ferritin (≤26 ng/mL) or higher ferritin (>26 ng/mL).
Trial registration: clinicaltrials.gov Identifier: NCT01555060.
Conflict of interest statement
Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Mast reported having received a grant from Novo Nordisk and honoraria from Siemens. No other disclosures were reported.
Figures
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
The Efficacy and Safety of Vitamin C for Iron Supplementation in Adult Patients With Iron Deficiency Anemia: A Randomized Clinical Trial.JAMA Netw Open. 2020 Nov 2;3(11):e2023644. doi: 10.1001/jamanetworkopen.2020.23644. JAMA Netw Open. 2020. PMID: 33136134 Free PMC article. Clinical Trial.
-
High-dose intravenous versus oral iron in blood donors with iron deficiency: The IronWoMan randomized, controlled clinical trial.Clin Nutr. 2020 Mar;39(3):737-745. doi: 10.1016/j.clnu.2019.03.025. Epub 2019 Mar 26. Clin Nutr. 2020. PMID: 30981629 Clinical Trial.
-
Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors.Cochrane Database Syst Rev. 2014 Jul 3;2014(7):CD009532. doi: 10.1002/14651858.CD009532.pub2. Cochrane Database Syst Rev. 2014. PMID: 24990381 Free PMC article. Review.
-
Serum ferritin in Danes: studies of iron status from infancy to old age, during blood donation and pregnancy.Int J Hematol. 1996 Feb;63(2):103-35. doi: 10.1016/0925-5710(95)00426-2. Int J Hematol. 1996. PMID: 8867722 Review.
Cited by
-
Supportive Care of Hematopoietic Stem Cell Donors.Clin Hematol Int. 2024 Feb 20;6(1):43-50. doi: 10.46989/001c.92460. eCollection 2024. Clin Hematol Int. 2024. PMID: 38817695 Free PMC article.
-
An iron rheostat controls hematopoietic stem cell fate.Cell Stem Cell. 2024 Mar 7;31(3):378-397.e12. doi: 10.1016/j.stem.2024.01.011. Epub 2024 Feb 22. Cell Stem Cell. 2024. PMID: 38402617
-
Clonal hematopoiesis in frequent whole blood donors.Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):299-304. doi: 10.1182/hematology.2023000483. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066913
-
Pilot Study to Gain First Indications for the Impact of a 3-Month's Oral Intake of a Sucrosomial Iron Supplement on Hemoglobin in Iron-Deficient Blood Donors.Transfus Med Hemother. 2022 Dec 6;50(4):286-293. doi: 10.1159/000527577. eCollection 2023 Aug. Transfus Med Hemother. 2022. PMID: 37767276 Free PMC article.
-
Impact of a post-donation hemoglobin testing strategy on efficiency and safety of whole blood donation in England: A modeling study.Transfusion. 2023 Mar;63(3):541-551. doi: 10.1111/trf.17277. Epub 2023 Feb 16. Transfusion. 2023. PMID: 36794597 Free PMC article.
References
-
- Baart AM, van Noord PAH, Vergouwe Y, et al. High prevalence of subclinical iron deficiency in whole blood donors not deferred for low hemoglobin. Transfusion. 2013;53(8):1670–1677. - PubMed
-
- Whitaker BI, Hinkins S. 2011 National blood collection and utilization survey report. US Dept of Health and Human Services; http://www.hhs.gov/ash/bloodsafety/2011-nbcus.pdf. Accessed November 25, 2014.
-
- Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood. 2011;118(12):3222–3227. - PubMed
-
- Brownlie T, IV, Utermohlen V, Hinton PS, Haas JD. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr. 2004;79(3):437–443. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- HHSN268201100001I/HL/NHLBI NIH HHS/United States
- HHSN268201100003C/WH/WHI NIH HHS/United States
- HHSN268201100006C/HL/NHLBI NIH HHS/United States
- HHSN268201100005I/HL/NHLBI NIH HHS/United States
- HHSN268201100001I/HL/NHLBI NIH HHS/United States
- HHSN268201100002C/WH/WHI NIH HHS/United States
- HHSN268201100004I/HL/NHLBI NIH HHS/United States
- HHSN268201100005C/HL/NHLBI NIH HHS/United States
- HHSN268201100003I/HL/NHLBI NIH HHS/United States
- HHSN268201100002I/HL/NHLBI NIH HHS/United States
- HHSN268201100001C/WH/WHI NIH HHS/United States
- HHSN268201100003I/HL/NHLBI NIH HHS/United States
- HHSN268201100002I/HL/NHLBI NIH HHS/United States
- HHSN268201100005I/HL/NHLBI NIH HHS/United States
- HHSN268201100005G/HL/NHLBI NIH HHS/United States
- HHSN268201100004I/HL/NHLBI NIH HHS/United States
- HHSN268201100004C/WH/WHI NIH HHS/United States
- HHSN268201100006I/PHS HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
